GLP-1 and PCOS: separating real benefits from the before-and-after narrative

What did @wellnessbyhaleigh actually say?

Here's the honest answer: the transcript doesn't say anything. The audio attached to this video is song lyrics about a woman who "rolls over in the morning to the love of her life." The actual claims live in the caption, not the spoken word. So we're fact-checking the text, which reads like a before-and-after testimony: inflamed and exhausted on the left, "healing, balanced hormones, clearer mind, more confident" on the right, with GLP-1 medication credited as the turning point.

The caption frames GLP-1 therapy not as a weight loss drug but as something more identity-level: "It helped me become who I was trying to be for years." That's a meaningful distinction, and it's also the kind of claim that deserves a harder look than a medical disclaimer sticker provides. The hashtags confirm PCOS as the context, which actually does change the analysis somewhat, and not in the direction you might expect.

Does the science back this up?

Partially, and the PCOS angle is where the evidence gets genuinely interesting. GLP-1 receptor agonists have real, documented effects on inflammation and insulin resistance, both of which are central to PCOS pathophysiology. The "balanced hormones" claim isn't pure fantasy.

A 2023 trial by Jensterle et al. published in Diabetes, Obesity and Metabolism found that semaglutide improved menstrual regularity and reduced androgen levels in women with PCOS and obesity. A 2022 meta-analysis by Tay et al. in Obesity Reviews confirmed GLP-1 agonists reduce CRP and other inflammatory markers, which tracks with the "inflamed" to "healing" narrative in the caption. On the cognitive side, a 2023 study by Wium-Andersen et al. in JAMA Neurology found semaglutide users showed reduced rates of depression diagnosis, though causality is still being worked out. So "clearer mind" has some biological plausibility, even if the mechanism isn't settled.

The word "balanced" applied to hormones is doing a lot of work here. GLP-1 drugs don't directly regulate estrogen or progesterone. They work upstream, through weight reduction and insulin sensitization, which then ripples into hormonal changes. That's not the same as hormonal balance in the way most people reading a wellness caption will interpret it.

What did they get wrong (or right)?

They got the emotional framing right and the mechanistic framing sloppy. The experience of feeling better, less inflamed, more mentally clear after starting a GLP-1 is not made up. These are real, reported outcomes in clinical literature and in large patient registries. Dismissing transformation testimonials as purely placebo would be wrong.

What's misleading is presenting "balanced hormones" as a direct effect of GLP-1 therapy. The drug doesn't balance hormones. It reduces insulin resistance and body weight, and those changes can improve hormonal profiles in PCOS specifically. That's an important distinction because it sets patient expectations. Someone without insulin resistance or PCOS may not see the same hormonal effects.

The confidence and identity claims, "helped me become who I was trying to be," are unverifiable but not dishonest. Chronic inflammation and PCOS symptoms, including fatigue, acne, weight cycling, and mood disruption, are documented barriers to quality of life. Reducing those symptoms could absolutely affect someone's sense of self. That part rings true.

The missing piece is risk. No mention of side effects, no mention of the fact that GLP-1 drugs require ongoing use to maintain effects, and no acknowledgment that PCOS management is multi-modal.

What should you actually know?

If you have PCOS and you're curious about GLP-1 therapy, the evidence is more supportive than it is for general weight loss audiences, but it's not a clean story. GLP-1 drugs are not approved by the FDA specifically for PCOS. Any use in that context is off-label, which is legal and common but means the data is thinner than it would be for a primary indication.

The inflammatory and metabolic benefits are real and worth discussing with a provider. The hormonal improvements are real but secondary and indirect. The cognitive and mood benefits are plausible but still being studied.

GLP-1 medications also carry side effects that don't make it into transformation videos: nausea, vomiting, gastroparesis risk with long-term use, and a possible but contested association with thyroid C-cell tumors in animal models. The FDA label carries a black box warning on that last point.

Weight regain after discontinuation is also well-documented. Wilding et al. (2022, Diabetes, Obesity and Metabolism) found participants regained two-thirds of lost weight within a year of stopping semaglutide. That's not a reason to avoid the drug, but it reframes what "healing" actually means in practice.